Alessandro Santarsiere

Dr. Alessandro Santarsiere

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
FSFABIANO SVOLACCHIA
FABIANO SVOLACCHIA
SBSergio Brongo
Sergio Brongo
ACAlessia Catalano
Alessia Catalano
CACeccarini Agostino
Ceccarini Agostino
LSLorenzo Svolacchia
Lorenzo Svolacchia
FGFederica Giuzio
Federica Giuzio
In this review, we summarize the most used natural products as useful adjuvants in BC by clarifying how these products may play a critical role in the prevention, treatment and progression of this disease. BC is the leading cancer, in terms of incidence, that affects women. The epidemiology and pathophysiology of BC were widely reported. Inflammation and cancer are known to influence each other in several tumors. In the case of BC, the inflammatory component precedes the development of the neoplasm through a slowly increasing and prolonged inflammation that also favors its growth. BC therapy involves a multidisciplinary approach comprising surgery, radiotherapy and chemotherapy. There are numerous observations that showed that the effects of some natural substances, which, in integration with the classic protocols, can be used not only for prevention or integration in order to prevent recurrences and induce a state of chemoquiescence but also as chemo- and radiosensitizers during classic therapy.

15 January 2024 in Medicina
Verified
Journal Article
Open access
PDF file
FFFrancesca Finelli
Francesca Finelli
ACAlessia Catalano
Alessia Catalano
MLMichele De Lisa
Michele De Lisa
GFGiuseppe Andrea Ferraro
Giuseppe Andrea Ferraro
SGSabino Genovese
Sabino Genovese
Carmela SaturninoCarmela Saturnino
Carmela Saturnino
The study of migraine is based on the complexity of the pathology, both at the pathophysiological and epidemiological levels. Although it affects more than a billion people worldwide, it is often underestimated and underreported by patients. Migraine must not be confused with a simple headache; it is a serious and disabling disease that causes considerable limitations in the daily life of afflicted people, including social, work, and emotional effects. Therefore, it causes a daily state of suffering and discomfort. It is important to point out that this pathology not only has a decisive impact on the quality of life of those who suffer from it but also on their families and, more generally, on society as a whole. The clinical picture of migraine is complex, with debilitating unilateral or bilateral head pain, and is often associated with characteristic symptoms such as nausea, vomiting, photophobia, and phonophobia. Hormonal, environmental, psychological, dietary, or other factors can trigger it. The present review focuses on the analysis of the physiopathological and pharmacological aspects of migraine, up to the correct dietary approach, with specific nutritional interventions aimed at modulating the symptoms. Based on the symptoms that the patient experiences, targeted and specific therapy is chosen to reduce the frequency and severity of migraine attacks. Specifically, the role of calcitonin gene-related peptide (CGRP) in the pathogenesis of migraine is analyzed, along with the drugs that effectively target the corresponding receptor. Particularly, CGRP receptor antagonists (gepants) are very effective drugs in the treatment of migraine, given their high diffusion in the brain. Moreover, following a ketogenic diet for only one or two months has been demonstrated to reduce migraine attacks. In this review, we highlight the diverse facets of migraine, from its physiopathological and pharmacological aspects to prevention and therapy.

Verified
Journal Article
Open access
PDF file
Maria FunicelloMaria Funicello
Maria Funicello
Lucia ChiummientoLucia Chiummiento
Lucia Chiummiento
ASAlessandro Santarsiere
Alessandro Santarsiere
FPFrancesco Poggio
Francesco Poggio
Paolo LupattelliPaolo Lupattelli
Paolo Lupattelli
Since the first cases of AIDS, reported in 1980, this disease has become chronic over the years, and researchers have been trying to keep it under control. Despite the development and spread of mutate viruses, HIV protease remains an important pharmacological target. In the development of new HIV protease inhibitors, heterocyclic fragments have proven to be of great importance, owing to their rigid core structure, which may fit better into the enzyme’s hydrophobic pockets, and the presence of a heteroatom, which may increase the number of H-bonding interactions at the active site. According to the concept of targeting the protein backbone, different aromatic or non-aromatic heterocyclic moieties have yielded inhibitors with sufficient activity against mutant viruses. This paper provides an overview of HIV protease inhibitors developed over the last fifteen years, with a focus on the presence of heterocycles in their structure, either in the core or on the side chains, which are crucial for their activity. The rationale behind the design of these new inhibitors, as well as the key synthetic steps involved in their preparation, is also described.

25 June 2025 in ACS Omega
Verified
Journal Article
Open access
ASAlessandro Santarsiere
Alessandro Santarsiere
PGPierantonio Galgano
Pierantonio Galgano
Maria FunicelloMaria Funicello
Maria Funicello
PLPaolo Lupattelli
Paolo Lupattelli
Lucia ChiummientoLucia Chiummiento
Lucia Chiummiento
A mild, efficient, eco-friendly method for the regioselective halogenation of arylboronic acids in water has been reported. A transition-metal-free ipso-chlorination of arylboronic acids was performed in water, yielding aryl chlorides. Ipso-brominated and iodinated compounds were obtained under the same conditions using the corresponding halide salts. This eco-friendly method operates efficiently, even on activated or nonactivated systems, with good yields and selectivity.

20 February 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
CCCarla Caddeo
Carla Caddeo
INIlaria Nigro
Ilaria Nigro
LCLucia Chiummiento
Lucia Chiummiento
MFMaria Funicello
Maria Funicello
Paolo LupattelliPaolo Lupattelli
Paolo Lupattelli
Antonio VassalloAntonio Vassallo
Antonio Vassallo

22 February 2024 in Viruses
Verified
Journal Article
Open access
PDF file
DAVIDE GENTILEDAVIDE GENTILE
DAVIDE GENTILE
Lucia ChiummientoLucia Chiummiento
Lucia Chiummiento
ASAlessandro Santarsiere
Alessandro Santarsiere
Maria FunicelloMaria Funicello
Maria Funicello
Paolo LupattelliPaolo Lupattelli
Paolo Lupattelli
Rosamaria PennisiRosamaria Pennisi
Rosamaria Pennisi
The continuous emergence of SARS-CoV-2 variants caused the persistence of the COVID-19 epidemic and challenged the effectiveness of the existing vaccines. The viral proteases are the most attractive targets for developing antiviral drugs. In this scenario, our study explores the use of HIV-1 protease inhibitors against SARS-CoV-2. An in silico screening of a library of HIV-1 proteases identified four anti-HIV compounds able to interact with the 3CLpro of SARS-CoV-2. Thus, in vitro studies were designed to evaluate their potential antiviral effectiveness against SARS-CoV-2. We employed pseudovirus technology to simulate, in a highly safe manner, the adsorption of the alpha (α-SARS-CoV-2) and omicron (ο-SARS-CoV-2) variants of SARS-CoV-2 and study the inhibitory mechanism of the selected compounds for cell–virus interaction. The results reported a mild activity against the viral proteases 3CLpro and PLpro, but efficient inhibitory effects on the internalization of both variants mediated by cathepsin B/L. Our findings provide insights into the feasibility of using drugs exhibiting antiviral effects for other viruses against the viral and host SARS-CoV-2 proteases required for entry.